Immunotherapy for Lung Cancer

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

PUBLISH ONLY Journal of Thoracic Oncology

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape Hawazin Faruki,

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

A Phase II Study of PF in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207 Paul Wheatley-Price, MBChB, MD, Quincy Chu,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Robert J Korst, MD, Ronald G Crystal, MD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Frank Detterbeck, MD Journal of Thoracic Oncology

Alterations of the Immune System in Thymic Malignancies

Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report Mitsuhiro Isaka, MD, Haruhiko Kondo,

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Mechanism of CTLA-4-induced immunosuppression.

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Prevention and Management of Bone Metastases in Lung Cancer: A Review

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PUBLISH ONLY Journal of Thoracic Oncology

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Mitotic Inhibitors Journal of Thoracic Oncology

The Number of Pulmonary Metastases: Influence on Practice and Outcome

Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study Marcello Carlo Ambrogi,

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

It’s All in the “Swerve of the Curve”

Pulmonary Metastasectomy in Breast Cancer

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

International Thymic Malignancies Interest Group: A Way Forward

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Releasing the Brakes on Cancer Immunotherapy

Vaccines for Lung Cancer

Neal S Goldstein, MD The Annals of Thoracic Surgery

Padmanee Sharma, James P. Allison Cell

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Immunotherapy for Lung Cancer Penelope A. Bradbury, MB BCh, FRACP, Frances A. Shepherd, MD, FRCPC Journal of Thoracic Oncology Volume 3, Issue 6, Pages S164-S170 (June 2008) DOI: 10.1097/JTO.0b013e318174e9a7 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Schematic diagram of cell specific immune system and mechanism of tumor cell evasion. APC indicates antigen-presenting cell; TL, T lymphocyte; CTL, cytotoxic T lymphocyte; MHC, major histocompatibility complex. Foreign antigen is phagocytosed by APCs (e.g., dendritic cells). Antigen is degraded into small peptide sequences that are displayed in combination with MHC II. The APC travels to draining lymph nodes and is in contact with naive T lymphocytes. The APC is activated by interacting with appropriate CD4+ T-helper cells, after which complementary CTLs are activated by the APC by interaction with MHC and costimulatory molecules. Activated CTLs circulate to the periphery searching for specific target. The CTLs induce apoptosis of target cells displaying complementary peptide in combination with MHC class I molecules. Journal of Thoracic Oncology 2008 3, S164-S170DOI: (10.1097/JTO.0b013e318174e9a7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan Meier curves of survival analysis for the l-BLP25 study. A, All patients. B, Patients with locoregional stage 3B disease. BLP indicates BLP25 liposome vaccine. Reproduced with permission from Butts C, Murray N, Maksymiuk A, et al. J Clin Oncol 2005;23:6674–6681. Journal of Thoracic Oncology 2008 3, S164-S170DOI: (10.1097/JTO.0b013e318174e9a7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier curves of survival analysis for the Bec2/BCG Study. A, Overall survival analysis. B, Survival of patients with and without humoral response. Reproduced with permission from Giaccone G, Debruyne C, Felip E, et al. J Clin Oncol 2005;23:6854–6864. Journal of Thoracic Oncology 2008 3, S164-S170DOI: (10.1097/JTO.0b013e318174e9a7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions